BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Codexis, Inc. (CDXS) Cuts 113, Hires New CFO


9/6/2012 8:16:55 AM

Silicon Valley / San Jose Business Journal by Diana Samuels, Technology Reporter

Codexis Inc., a company that makes environmentally friendly chemicals, fuels and pharmaceutical processes, said Tuesday it will lay off 133 people.

The layoffs are necessary because the Redwood City-based company is ending an agreement it had with Royal Dutch Shell Plc and will lose ongoing funding, a statement from the company said. Codexis (Nasdaq: CDXS) reported having 347 employees total as of last year, so the loss is more than a third of its staff. The layoffs will be effective Oct. 30.

The company ended its research agreement with Shell two months early, effective Aug. 31. Shell will pay Codexis $7.5 million to satisfy the contract.

Codexis also signed a new agreement with Shell that will allow Codexis to sell some of its products, developed as part of its relationship with Shell, to other companies. It can now commercialize its biofuels enzymes and sell them to other companies, though Codexis will have to give Shell preferential pricing and a royalty on its sales to other companies.

Codexis’ technology re-engineers enzymes and microorganisms to do things like transform waste biomass into fuel and make affordable industrial chemicals from sustainable sources.

Codexis also announced a shareholder rights plan to guard the company against takeover offers. The rights aren’t being distributed in response to any specific effort to take over the company, the company’s press release said.

In addition, the company announced a new CFO. David O’Toole, a former CFO at Response Genetics, joins the company beginning Tuesday. He was also CFO at Abraxis Bioscience, and spent 16 years at accounting firm Deloitte LLP.

Codexis’ previous interim CFO, Brian Dowd, left in June. According to his LinkedIn profile, he now works for Foster City-based Mondee, a travel and technology group. He had replaced Robert Lawson, who was hired by cloud phone system company RingCentral.



Read at San Jose Business Journal
Read at Nasdaq
Read at News Release
Read at News Release

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES